We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$333M
AUM Growth
+$77.5M
Cap. Flow
+$78M
Cap. Flow %
23.42%
Top 10 Hldgs %
35.62%
Holding
104
New
20
Increased
33
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$11M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$7.71M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.79M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$4.71M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$3.07M
4
ZBH icon
Zimmer Biomet
ZBH
+$2.8M
5
AET
Aetna Inc
AET
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
76
Cardiff Oncology
CRDF
$77.2M
$1.13M 0.34%
2,730
-48
-2% -$20.8K
IMGN
77
DELISTED
Immunogen Inc
IMGN
$1.1M 0.33%
73,702
-26,298
-26% -$415K
INFI
78
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.09M 0.33%
132,766
-77,234
-37% -$1.04M
EXEL icon
79
Exelixis
EXEL
$13.4B
$1.04M 0.31%
294,805
-55,195
-16% -$376K
VIRX
80
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$974K 0.29%
+702
New +$816K
MTEM
81
DELISTED
Molecular Templates, Inc.
MTEM
$936K 0.28%
1,191
-324
-21% -$263K
VOLC
82
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$872K 0.26%
44,221
-779
-2% -$16.7K
MYGN icon
83
Myriad Genetics
MYGN
$312M
$840K 0.25%
24,568
-56,191
-70% -$1.74M
BIND
84
DELISTED
BIND THERAPEUTICS INC
BIND
$718K 0.22%
+60,000
New +$784K
HAE icon
85
Haemonetics
HAE
$4B
$653K 0.2%
20,047
-9,953
-33% -$380K
SRNE
86
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$630K 0.19%
+49,135
New +$544K
MGNX icon
87
MacroGenics
MGNX
$257M
$557K 0.17%
+20,000
New +$706K
LUMO
88
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$557K 0.17%
2,178
-2,266
-51% -$693K
LXRX icon
89
Lexicon Pharmaceuticals
LXRX
$1.1B
$510K 0.15%
42,115
-742
-2% -$9.48K
ANTH
90
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$395K 0.12%
14,740
-172
-1% -$4.37K
A icon
91
Agilent Technologies
A
$41.2B
– –
-55,920
Closed -$2.29M
HOLX
92
DELISTED
Hologic
HOLX
– –
-72,000
Closed -$1.61M
IART icon
93
Integra LifeSciences
IART
$1.34B
– –
-110,091
Closed -$2.15M
INVA icon
94
Innoviva
INVA
$1.48B
– –
-163,812
Closed -$4.71M
ISRG icon
95
Intuitive Surgical
ISRG
$134B
– –
-72,000
Closed -$3.07M
MDGL icon
96
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-2,857
Closed -$524K
RVTY icon
97
Revvity
RVTY
$12.8B
– –
-45,000
Closed -$1.85M
ZBH icon
98
Zimmer Biomet
ZBH
$18.4B
– –
-30,900
Closed -$2.8M
MDRX
99
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-55,000
Closed -$850K
AGN
100
DELISTED
Allergan plc
AGN
– –
-10,000
Closed -$1.68M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rhenman & Partners Asset Management held 104 positions worth $333M, up 30% from $256M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rhenman & Partners Asset Management deployed $78M of net new capital in Q1 2014, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Pfizer: 372,050 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 83% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $3.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2014 buy was Pfizer: 372,050 shares worth $11.3M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q1 2014, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $3.6M.
  • Rhenman & Partners Asset Management fully exited Innoviva in Q1 2014, selling an estimated $4.71M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 36% of its $333M portfolio in Q1 2014.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 13 in Q1 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $333M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2014, filed 14 May 2014.